Minghui Pharmaceutical

Based in China, Minghui Pharmaceutical is a global leader in developing and distributing innovative pharmaceutical products, focusing on addressing critical healthcare needs across various therapeutic areas. Minghui Pharmaceutical, founded in 2018 and headquartered in Shanghai, China, specializes in the development of pharmaceutical products. The company has successfully completed one funding round, raising a total of USD 131. 00 mn in a PRE-IPO round on August 7, 2025, with investors including OrbiMed Advisors and Qiming Venture Partners.

Minghui Pharmaceutical specializes in the development and distribution of innovative pharmaceutical products aimed at addressing critical healthcare needs. The company's core product offerings include a range of prescription medications targeting chronic and acute conditions, particularly in oncology, cardiology, and infectious diseases. Each product is meticulously formulated to enhance patient outcomes for healthcare providers and patients across multiple demographics. The company has strategically launched its products in key markets such as North America, Europe, and parts of Asia, ensuring broad accessibility and collaboration with healthcare institutions.

Minghui Pharmaceutical generates revenue through a structured model focused on B2B transactions with healthcare providers and institutions. Revenue streams include direct sales of pharmaceutical products, often sold through distribution partners to hospitals and clinics. The company also engages with local wholesalers to guarantee product availability across its served regions. The pricing structure reflects the value provided by their medications, catering to both standard and specialty healthcare needs.

In August 2025, Minghui Pharmaceutical raised USD 131. 00 mn in pre-IPO funding, primarily to support late-stage clinical programs and preparations for commercialization of PD-1/VEGF bispecific and ADC combination therapies, as well as a topical JAK inhibitor. The funding will enable the company to advance its pipeline and ensure readiness for its initial public offering. Minghui aims to expand its product line and market presence, particularly targeting new regions in North America and Europe by 2026.